Literature DB >> 21290233

β-Adrenergic Receptor Subtypes in the Urinary Tract.

Martin C Michel1.   

Abstract

Within the urinary tract, β-adrenergic receptors (AR) are found largely on smooth muscle cells but are also present, at least in the bladder, in the urothelium and on afferent nerves. Our understanding of β-AR subtype expression and function is hampered by a lack of well-validated tools, particularly with regard to β(3)-AR. Moreover, the β-AR subtypes involved in a specific function may differ between species. In the ureter, β-AR can modulate pacemaker activity and smooth muscle tone involving multiple subtypes. In the human bladder, β-AR promote urine storage. Bladder smooth muscle relaxation primarily involves β(3)-AR, and the agonists selective for this subtype are in clinical development to treat bladder dysfunction. While prostate and urethra also express β-AR, the overall physiological role in these tissues remains unclear.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21290233     DOI: 10.1007/978-3-642-16499-6_15

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  10 in total

Review 1.  Translational Research and Functional Changes in Voiding Function in Older Adults.

Authors:  Florenta Aura Kullmann; Lori Ann Birder; Karl-Erik Andersson
Journal:  Clin Geriatr Med       Date:  2015-07-23       Impact factor: 3.076

2.  Expression of β-adrenergic receptor subtypes in human normal and dilated ureter.

Authors:  Hailin Shen; Zhipeng Chen; Al-Dhabi Mokhtar; Xiaojun Bi; Guolin Wu; Shide Gong; Chuanyang Huang; Shuai Li; Shuqi Du
Journal:  Int Urol Nephrol       Date:  2017-07-29       Impact factor: 2.370

3.  Do β-adrenoceptor agonists induce homologous or heterologous desensitization in rat urinary bladder?

Authors:  Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-10       Impact factor: 3.000

Review 4.  Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease.

Authors:  M Archer; N Dogra; Z Dovey; T Ganta; H-S Jang; J A Khusid; A Lantz; M Mihalopoulos; J A Stockert; A Zahalka; L Björnebo; S Gaglani; M R Noh; S A Kaplan; R Mehrazin; K K Badani; P Wiklund; K Tsao; D J Lundon; N Mohamed; F Lucien; B Padanilam; M Gupta; A K Tewari; N Kyprianou
Journal:  Cell Commun Signal       Date:  2021-07-20       Impact factor: 5.712

5.  The cAMP effector EPAC activates Elk1 transcription factor in prostate smooth muscle, and is a minor regulator of α1-adrenergic contraction.

Authors:  Martin Hennenberg; Frank Strittmatter; Henning Schmetkamp; Beata Rutz; Sebastian Walther; Christian G Stief; Christian Gratzke
Journal:  J Biomed Sci       Date:  2013-07-02       Impact factor: 8.410

Review 6.  The aging bladder insights from animal models.

Authors:  Lori A Birder; Aura F Kullmann; Christopher R Chapple
Journal:  Asian J Urol       Date:  2017-05-26

7.  Detrusor Overactivity May Be a Prognostic Factor for Better Response to Combination Therapy Over Monotherapy in Male Patients With Benign Prostatic Enlargement and Storage Lower Urinary Tract Symptoms.

Authors:  Vasileios Sakalis; Vasileios Sfiggas; Ioannis Vouros; George Salpiggidis; Athanasios Papathanasiou; Apostolos Apostolidis
Journal:  Int Neurourol J       Date:  2020-12-31       Impact factor: 2.835

8.  Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors.

Authors:  Kai Sun; Di Wang; Gang Wu; Jian Ma; Tianqi Wang; Jitao Wu; Jipeng Wang
Journal:  Cancer Med       Date:  2021-09-21       Impact factor: 4.452

Review 9.  Clinical Utility of β3-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations.

Authors:  Jan Krhut; Barbora Skugarevská; David Míka; Lars Lund; Peter Zvara
Journal:  Res Rep Urol       Date:  2022-04-26

10.  Pharmacology of the lower urinary tract.

Authors:  Martin Hennenberg; Christian G Stief; Christian Gratzke
Journal:  Indian J Urol       Date:  2014-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.